Title: Expression and clinical significance of c-MET m RNA in primary lung adenocarcinoma: An analysis of 83 cases
Abstract: Objective To investigate the expression and clinical significance of c-MET m RNA in primary lung adenocarcinoma. Methods Clinical data and c-MET m RNA test results about 83 patients with primary lung adenocarcinoma who underwent surgery in our hospital from July 2011 to October 2013 were retrospectively analyzed. Patients were divided into c-MET m RNA overexpression group and low expression group. Results In 83 patients, the constituent ratio of overexpression group was 36.1%(30/83). The lymph node metastasis rate of overexpression group and low expression group were 46.7%(14/30) and 20.8%(11/53) with significant difference(P 0.05). The Ⅰ, Ⅱ, Ⅲ TNM stage of overexpression group and low expression group were 53.3%(16/30), 30.0%(9/30), 16.7%(5/30) and 75.5%(40/53), 17.0%(9/53), 7.5%(4/53), which also showed significant differences(P 0.05). The 1-, 2-year progression-free survival rate of overexpression group and low expression group were 53.3%, 22.2% and 81.1%, 67.9% with significant difference(P 0.05). The multivariate analysis showed that c-MET m RNA level(HR=2.298, P=0.019), differentiation(HR=2.632, P=0.003) and TNM stage(HR=3.048, P=0.019) were independent risk factors for prognosis. Conclusion c-MET m RNA overexpression is a negative prognostic factor for patients with primary lung adenocarcinoma.
Publication Year: 2015
Publication Date: 2015-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot